Skip to main content
OpenTrials
Completed

NCT Number: NCT03325257

Post-ATU Study of Nivolumab

Nivolumab obtained European Marketing authorization in June 2015. Before this date, a Temporary Authorization for Use (ATU) Program in France for nivolumab was set up between September 2014 and August 2015. This program enrolled approximately 600 melanoma patients (unresectable or metastatic).

It appears relevant to conduct a study on patients treated during the ATU to assess thoroughly patient characteristics, efficacy, safety, and patterns of use of nivolumab in real-life conditions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Melanoma Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Neuroectodermal Tumors Neuroendocrine Tumors Nevi and Melanomas Skin Diseases Skin Neoplasms Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

AP-HP Hôpital Ambroise Paré, Paris, Boulogne Billancourt, France

Loading trial locations.

About this study

In order to reach goals of this study, collaboration had been established between BMS and the RIC-Mel network (network for Research and Clinical Investigational Research on Melanoma) (NCT03315468).

The RIC-Mel network has set up a national database in order to reference the active file of melanoma patients in France. The RIC-Mel database, supported by Nantes University Hospital, had been approved by French authorities (CCTIRS and CNIL). The RIC-Mel network is coordinated by Pr B. DRENO (Nantes University Hospital) and Pr C. LEBBE (Saint-Louis Hospital, AP-HP, Paris). Nowadays, 49 centres located all over the country are participating, with more than 19,000 melanoma patients included in the database. The RIC-Mel database is referred as one of the privileged access to any research program on melanoma by the Cancerology Group (GCC) of the French Society of Dermatology .

Based on this, BMS and the RIC-Mel network had established a partnership to set up a study in order to estimate the overall survival of melanoma patients treated by Nivolumab during the French ATU program.

Data are collected in the RIC-Mel database by participating centres. Information of centres, follow-up of activity, data reviewing and extractions are realized by the RIC-Mel network. Data analysis is performed by BMS following a developed statistical protocol.

Patients included in the study were patients with unresectable or advanced metastatic melanoma, which received at least one of Nivolumab, dispensed during the French ATU program.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with unresectable or metastatic melanoma cared in participating sites,
  • Patients included in French nivolumab ATU program,
  • Patients treated by at least one perfusion of nivolumab,
  • Patients agreed to participate to the study.

Exclusion criteria

  • Patients with unresectable or metastatic melanoma not included in French nivolumab ATU program,
  • Patients having initiated Nivolumab after the 31th December 2015,
  • Patients disagreed to participate.

Treatment and study plan

Routine care

Other

This study is an observational one - there is no change to the routine care. Patients received the Nivolumab independently of the study. Only data will be collected during this project.

Primary outcomes

  1. Overall Survival of patients included in the study thanks to subgroups of interest

    Time frame: 2 years

    Overall survival is defined as the time from index date (initiation of Nivolumab) until date of death due to any cause. Overall survival will be censored on the last date a subject was known to be alive. Estimates of survival rates will be realized for 1-year and 2-year survival. Median time will also be calculated.

    Subgroups of interest are described in the description of the first Secondary Outcome Measure.

    Safety Issue: No

Secondary outcomes

  1. Distribution of melanoma patients included in the study in all subgroups of interest thanks to their clinical features at the time of treatment initiation

    Time frame: Day 1

    Subgroups of interest, based on information collected in medical records, were :

    • ECOG performance status (PF). ECOG PF is attempted to quantify cancer patients' general well-being and activities of daily life. The classifications were 0, 1 or ≥2.
    • LDH level. This level is considered as a prognostic factor: higher the LDH level, the worst the prognosis. The classifications were ≤Upper Limit of Normal (ULN), >ULN, >2 ULN or N/R (Unknown).
    • History of brain metastasis. These metastases are considered as one of the most difficult-to-treat complications of melanoma. The classifications were No or Yes.
    • Line of therapy. The classifications were 0, 1, 2 or >2.
    • BRAF status. BRAF is a proto-oncogene. Melanoma patients with BRAF mutation are eligible to targeted therapy.The classifications were Yes (mutated), No (wild-type) and Unknown (no research).
    • Number of metastatic sites. Safety Issue: No

  2. Proportion of melanoma patients included in the study categorized by genders overall and by subgroups of interest

    Time frame: Day 1

    Distribution of females and males. This analyse will be performed for all the study population and by subgroups of interest (as defined in the primary Outcome Measure).Safety Issue: No

  3. Distribution of age of melanoma patients included in the study overall and by subgroups of interest

    Time frame: Day 1

    Age of patients is the age at the start of Nivolumab treatment Safety Issue: No

  4. Description of Nivolumab treatment of melanoma patients included in the study

    Time frame: 2 years

    Average and median of Nivolumab treatment duration and infusion number will be assessed. Median time to discontinuation, whatever the reason and median time to discontinuation of dose related to adverse events. Distribution of reasons for discontinuation.

    Safety Issue: No

  5. Incidence of select grade 3, 4 and 5 adverse events (AE) in melanoma patients included in the study and related to Nivolumab treatment

    Time frame: 2 years

    An AE is defined as any undesirable experience or manifestation associated with the use of a medical product in a patient. AEs are categorized by grades, which refer to severity : Grade 3 - Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self-care activities of daily living, Grade 4 - Life-threatening consequences, urgent intervention indicated, Grade 5 - Death related to AE. Proportion of patients with at least one or more select AE, distribution, average and median time of AE occurrence, duration and evolution of AEs as well as description of action on Nivolumab treatment will also be assessed.

    Safety Issue: Yes

  6. Progression-free survival of melanoma patients included in the study

    Time frame: 2 years

    Progression-free survival is defined as the time since Nivolumab initiation to either the first disease progression date or at last known tumour assessment date, or death due to any cause, whichever occurs first.

    Safety Issue: No

  7. Objective response rate of melanoma patients included in the study

    Time frame: 2 years

    Objective response rate as the number of subjects with a best objective response of either a partial response of a complete response. Objective response rate is the proportion of patients with an objective response. Safety Issue: No

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Collaborators

  • Bristol-Myers Squibb

Registry information

Official study title

Two-years Follow-up of Melanoma Patients Treated by Nivolumab During the French ATU Program

Acronym: Post-ATU

Important dates

Study start
2017
Primary completion
2018
Study completion
2019
First posted
Oct 30, 2017
Registry last updated
Sep 14, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.